Scientific Advisory Board
The WuXi Biologics Scientific Advisory Board membership represents a broad range of scientific disciplines in biologics research and development in the fields of synthetic biology, antibody therapeutics, protein engineering, analytical sciences, virology, vaccines, and cell culture bioprocessing and bioengineering. In addition, the SAB members are also thought leaders and entrepreneurs, collectively founding more than forty successful biotech companies.
Brief biographies of the SAB members are listed below.
James Larrick, MD/PhD
Dr. James Larrick is Founder, Managing Director, Scientific Director of Panorama Research Institute and Managing Director & Chief Medical Officer of Velocity Pharmaceutical Development.
Dr. Larrick holds MD and PhD degrees from Duke University School of Medicine and is a pioneer of the biotechnology industry. He is an outstanding biomedical entrepreneur with an international reputation in cytokines, therapeutic antibodies, molecular biology, and pharmaceutical drug development. He has written or coauthored eight books, over 250 papers/chapters, over 30 patents, and served on the editorial boards of six journals. In 1991, Jim founded the Panorama Institute of Molecular Medicine (PRI) which has incubated more than 20 life science projects, leading to his co-founding more than a dozen companies. To date, PRI-initiated projects and/or companies have led to five IPOs and numerous successful acquisitions.
Ram Sasisekharan, PhD
Dr. Ram Sasisekharan is an Alfred H. Caspary Professor of Biological Engineering and Health Sciences & Technology in Massachusetts Institute of Technology.
Dr. Sasisekharan received his PhD in Medical Sciences from Harvard Medical School and has been a professor of Biological Engineering at MIT since 1996 and served as the Director of the Harvard-MIT Division of Health Sciences & Technology from 2008-2012. Dr. Sasisekharan’s Laboratory employs multidisciplinary strategies to develop and integrate technologies to further study complex biological systems important to a host of disease processes. He has co-authored 5 books, over 210 papers/chapters, over 85 patents, and served on the editorial boards of 4 journals. Technologies developed in the Sasisekharan Lab have resulted in the founding of multiple local biotechnology companies, including Momenta Pharmaceuticals, Cerulean, Visterra and Tychan. Dr. Sasisekharan has received numerous awards, including National Institutes of Health Merit Award in 2010, American Institute for Medical and Biological Engineering (AIMBE) Fellow in 2009, and Fellow of the U.S. National Academy of Inventors in 2014 to name a few.
David D. Ho, MD
Dr. David D. Ho is Scientific Director and CEO of the Aaron Diamond AIDS Research Center, as well as the Irene Diamond Professor at the Rockefeller University.
Dr. Ho received his MD from Harvard Medical School in 1978 and has a long distinguished academic career at Massachusetts General Hospital and Harvard Medical School in 1985-1986; UCLA School of Medicine in 1986-1990; and NYU School of Medicine in 1990-1996. Since 1990, Dr. Ho has been Scientific Director and CEO of Aaron Diamond AIDS Research Center; he is also Professor and Physician at the Rockefeller University. David has also been a reviewer, a member of editorial board, and/or editor of many scientific journals. Dr. Ho received over 40 awards and honors, including Man of the Year, Time Magazine in 1996; Fellow, American Academy of Arts and Sciences; Member of National Academy of Medicine; Member of Chinese Academy of Engineering; 14 honorary doctorates; and the US Presidential Medal.
Wei-Shou Hu, PhD
Dr. Wei-Shou Hu is a Distinguished McKnight University Professor at University of Minnesota.
Dr. Hu received his PhD in Biochemical Engineering from Massachusetts Institute of Technology. He pioneered the bioprocess technology field and initiated the Engineering Foundation Conference on Cell Culture Engineering twenty-eight years ago that has had a great impact on the biotech industry. Dr. Hu’s current research efforts emphasize exploiting genomics and proteomics in advancing bioprocess technology, and applying systems analysis to generate new understanding of metabolic and gene expression regulation. Over the past quarter century, Dr. Hu helped train thousands of scientists and engineers for pharmaceutical and biotech industry around the world and authored several widely used textbooks on bioprocess engineering. He is a recipient of numerous awards for his contributions in the biochemical engineering field.
David R. Liu, PhD
Dr. David R. Liu is Professor of Chemistry and Chemical Biology at Harvard University, Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute, and Howard Hughes Medical Institute (HHMI) Investigator, as a member of its Scientific Advisory Board (SAB).
Prof. Liu’s research and teaching have earned distinctions including the Ronald Breslow Award, the Pure Chemistry Award, and the Arthur C. Cope Scholar Award. In 2017, he was named to the Nature’s 10 researchers in world, and base editing, a next-generation genome editing technology, was one of four finalists for Science magazine’s 2017 Breakthrough of the Year. Prof. Liu has published more than 160 papers and is the inventor of more than 60 issued patents. He is the founder or co-founder of five biotechnology companies, including Editas Medicine, Pairwise Plants, and Beam Therapeutics.